Long-term disease control in a patient with metastatic sigmoid cancer treated with trifluridine/tipiracil - case report
Abstract
We report the case of a patient with metastatic sigmoid cancer harboring a KRASG12D mutation who achieved a long-term disease control on a third line trifluridine/tipiracil therapy. The case demonstrates that some patients may derive a significant benefit from trifluridine/tipiracil therapy despite the presence of a prognostically unfavorable KRAS mutation.
Clinical and laboratory factors typically associated with a favorable prognosis were found in this patient (<= 2 metastatic sites, absent liver metastases, alkaline phosphatase level < 300 IU/L, trifluridine/tipiracil dose reductions, and neutrophil/lymphocyte ratio < 5). Prospective validation of these variables as prognostic and/or predictive factors and deeper underrstanding of the role of specific mutations may aid in the therapy decision-making process in the future.